Kanglin Biotec
Latest round
- Series A
Last raised
- Nov 2024
Total raised
- $21M
Investors
- 2
About Kanglin Biotec
Based in Hangzhou, China, and founded in 2015, Kanglin Biotec operates as a developer of innovative gene therapy drugs, mainly engaged in the research and development of gene therapy and cell therapy technologies. The company has cooperated with Shanghai Public Health Clinical Center, Guangdong Medical University Affiliated Hospital, and Hangzhou First People's Hospital. It is a National High-Tech enterprise. Kanglin Biotec specializes in innovative gene therapies aimed at addressing chronic ailments through functional cures. The company's technology platforms include adeno-associated virus vector platform, lentivirus vector platform, and hematopoietic stem cell vector platform. Its products focus on advanced genetic modification techniques that enables precise targeting of disease mechanisms, thereby improving patient outcomes in areas such as oncology, genetic disorders, and autoimmune diseases. The company generates revenue by providing technical services such as preparation of lentiviral vectors, T cell transduction and T cell gene editing.
Who invested in Kanglin Biotec
2 investors across 1 round
See all investors in Kanglin Biotec
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 11, 2024
Amount
$21M
Investors
Questions about Kanglin Biotec
Who invested in Kanglin Biotec?
Kanglin Biotec has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kanglin Biotec raised?
Kanglin Biotec has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Kanglin Biotec last raise money?
Kanglin Biotec's most recent round on record is a Series A, in Nov 2024.
What does Kanglin Biotec do?
Based in Hangzhou, China, and founded in 2015, Kanglin Biotec operates as a developer of innovative gene therapy drugs, mainly engaged in the research and development of gene therapy and cell therapy technologies.
Where is Kanglin Biotec headquartered?
Kanglin Biotec is headquartered in Hangzhou, China.
Which VCs invest in companies like Kanglin Biotec?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Kanglin Biotec's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Kanglin Biotec? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.